Aug 14
|
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
|
Aug 12
|
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
|
Jul 31
|
Hemostemix Increases Previously Closed Private Placement to $3,000,000
|
Jul 31
|
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
|
Jul 24
|
Hemostemix Closes $2,969,600 Private Placement
|
Jul 23
|
Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
|
Jul 2
|
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
|
Jun 27
|
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
|
Jun 26
|
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
|
May 12
|
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
|
May 8
|
Hemostemix at Invest Stuttgart
|
Mar 14
|
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
|
Mar 12
|
Life Sciences Investor Forum Agenda Announced for March 13th
|
Feb 20
|
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
|
Feb 19
|
Hemostemix Licenses CytoImmune's BioReactor Technologies
|
Feb 14
|
Hemostemix Provides Corporate Update
|
Feb 11
|
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
|
Feb 10
|
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
|
Jan 2
|
Hemostemix is Up-Listing in the USA to Generate Liquidity
|
Dec 31
|
Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction
|